United Therapeutics Corporation

NASDAQ:UTHR

Biotechnology

Healthcare
$577.34 -3.27%

-$18.01 today

Market cap
$24.59B
Beta
0.57
P/E (TTM)
18.0
EPS (TTM)
$29.60
52W Low $272.12High $609.35

Volume 0.42M

Average 0.52M

UTHR Interest Expense

Cost of servicing the company's debt during the period.

United Therapeutics CorporationNASDAQ: UTHR

Interest Expense · Q2 FY2026 · quarter ended Jun 2026

Interest expense declines year over year

Q2 FY2026 interest expense of $2.9M fell 60.3% year over year, ahead of the -61.8% change in trailing-twelve-month interest expense. Sequentially, it fell 3.3% from the prior quarter. Over 3 fiscal years it compounded at -15.6% a year.

Context

  • Interest expense amounted to 0.6% of revenue in FY2025, down 0.9 pp from a year earlier.
  • Interest expense increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -60.3% holds above the trailing-twelve-month pace of -61.8%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$2.9M-3.3% QoQ
Last fiscal yearDec 2025
$19.5M-54.5% YoY
LTMJun 2026
$12M-61.8% YoY
Interest Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-60.3%——
1 year-54.5%——
3-year CAGR-15.6%——
5-year CAGR——
10-year CAGR——

Interest Expense history

USD · from the income statement

Latest · FY2025
19.5M USD
Year-over-year change
-54.5%
4-year CAGR
+1.2%

Interest Expense vs competitors

How UTHR compares with its peers on the latest reported figures

  • UTHR's LTM Jun 2026 interest expense of $12M is the 3rd highest of the 5 companies compared; the peer median is $15.61M.
  • Its year-over-year change of -61.8% is the lowest of 4, against a peer median of -4.8%.
  • Interest expense amounts to 0.4% of revenue for UTHR, versus a peer median of 5.9%.
UTHR Competitors Peer median
Interest Expense for UTHR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
INSMInsmed IncorporatedLTM Jun 2026$81.34M -4.8%+46.9%7.1%
LQDALiquidia CorporationLTM Jun 2026$26.63M +50.6%+117.8%5.9%
UTHRUnited Therapeutics CorporationLTM Jun 2026$12M -61.8%-15.6%0.4%
TVTXTravere Therapeutics, Inc.LTM Sep 2026$4.59M -59.3%-0.8%0.7%
IKTInhibikase Therapeutics, Inc.LTM Mar 2026$0 ———
Peer median (excluding UTHR) $15.61M-4.8%+46.9%5.9%

Competitors are the stored peer set for UTHR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.69B1.94B2.33B2.88B3.18B
Cost of Revenue122.5M146.7M257.5M309.7M384.4M
Gross Profit1.56B1.79B2.07B2.57B2.8B
Gross Margin92.7%92.4%88.9%89.2%87.9%
Research & Development540.1M322.9M408M481M550M
Selling, General & Admin467M487M477.1M638.6M731.1M
Operating Expenses1.01B809.9M885.1M1.19B1.28B
Depreciation & Amortization49.9M51.3M53.2M72.5M85.6M
EBITDA736.8M1.04B1.39B1.65B1.82B
EBITDA Margin43.7%53.7%59.6%57.5%57.2%
Operating Income555.9M979.7M1.18B1.38B1.52B
Operating Margin33.0%50.6%50.9%47.9%47.7%
Interest Income16.7M45.2M162.7M199.1M192M
Interest Expense18.6M32.4M59.3M42.9M19.5M
Other Income / Expenses38M(29.1M)89.4M162M196.7M
Income Before Tax593.9M950.6M1.27B1.54B1.71B
Pre-Tax Margin35.2%49.1%54.7%53.5%53.9%
Income Tax Expense118.1M223.3M289.5M343.9M379.2M
Net Income475.8M727.3M984.8M1.2B1.33B
Net Margin28.2%37.6%42.3%41.5%41.9%
EPS (Basic)10.6015.9821.0426.4430.13
EPS (Diluted)10.0615.0019.8124.6427.86
Weighted Avg Shares44.9M45.5M46.8M45.2M44.3M
Weighted Avg Shares (Diluted)47.3M48.5M49.7M48.5M47.9M

United Therapeutics Corporation

NASDAQ:UTHR

Intrinsic Alpha fair value

Locked

Current Price

$577.34

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.